Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

Quetiapine

Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.

Trial Locations (1)

93053

University of Regensburg, Department of Psychiatry, Regensburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Regensburg

OTHER